Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Parecoxib + celecoxib is a sequential analgesic regimen consisting of intravenous parecoxib followed by oral celecoxib. This combination therapy utilizes two selective COX-2 inhibitors for postoperative pain management. Parecoxib is a water-soluble injectable prodrug of valdecoxib that can be used perioperatively when patients are unable to take oral medications. Celecoxib is an oral COX-2 selective inhibitor that provides continued pain relief after the initial parecoxib administration. The sequential regimen has been shown to reduce morphine consumption, achieve better pain control, improve functional recovery, and lead to fewer adverse events compared to placebo in various surgical settings.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on parecoxib + celecoxib.